Pharnext to Showcase Pioneering PLEOTHERAPY™ R&D Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference
June 20 2017 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a
biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that Xavier Paoli,
Chief Commercial Officer and Vice President of R&D Operations
and Rodolphe Hajj, Ph.D., Chief Pharmacology Officer, will present
at the 6th Annual Drug Repositioning, Repurposing and Rescue
Conference in Chicago, USA on Tuesday, June 27, 2017.
Details are as follow:
Date
Time
Location
Tuesday, June 27, 2017 11.00am CDT Radisson Blu Aqua
Hotel, Chicago
Their presentation, “A New Drug Discovery Paradigm Pioneered by
Pharnext: PLEOTHERAPY™,” will offer insights into the Company’s
innovative R&D paradigm. The PLEOTHERAPY™ R&D platform is
universally applicable to any disease or compound, regardless of
development stage or lifecycle status. It allows the identification
and development of synergistic combinations of repositioned drugs
at new optimal lower doses, known as PLEODRUG™. The presentation
will also be an opportunity for the speakers to introduce
Pharnext’s business model and growth strategy for years to
come.
In addition, Dr. Hajj will participate in an expert panel
discussion titled, “New Technologies and Methods to Advance
Systematic Repurposing” on Tuesday, June 27, at 12:55 pm CDT.
If you are interested in meeting Mr. Paoli or Dr. Hajj at the
event, please send an email to contact@pharnext.com.
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property including several product or composition of matter patents
already granted. The Company is supported by a world-class
scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170620006003/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30VP, Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorMedia Relations
(Europe)ALIZE RPCaroline Carmagnol / Margaux Pronost+33 (0)1 44
54 36 64pharnext@alizerp.comorInvestor Relations (U.S.)Stern
Investor Relations, Inc.Sarah McCabe, +1
212-362-1200sarah@sternir.comorMedia Relations (U.S.)Russo
PartnersTony Russo, +1 212-845-4251Scott Santiamo, +1
718-344-5843tony.russo@russopartnersllc.comscott.santiamo@russopartnersllc.comorFinancial
Communication (France)NewCapEmmanuel Huyn, +33 (0)1 44 71 20
40pharnext@newcap.eu
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024
